Pacific Biosciences of California  

(Public, NASDAQ:PACB)   Watch this stock  
Find more results for PACB
-0.28 (-3.27%)
Real-time:   10:07AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.29 - 8.63
52 week 3.58 - 14.00
Open 8.53
Vol / Avg. 181,552.00/1.58M
Mkt cap 769.90M
P/E     -
Div/yield     -
EPS -0.39
Shares 87.17M
Beta 3.02
Inst. own 76%
Aug 4, 2016
Q2 2016 Pacific Biosciences of California Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Pacific Biosciences of California Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 15, 2016
Pacific Biosciences of California Inc at William Blair Growth Stock Conference
May 19, 2016
Pacific Biosciences of California Inc Annual Shareholders Meeting (Estimated)
May 17, 2016
Pacific Biosciences of California Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -101.18% -34.16%
Operating margin -97.06% -56.24%
EBITD margin - -52.27%
Return on average assets -57.23% -24.80%
Return on average equity -95.64% -49.34%
Employees 394 -
CDP Score - -


1380 Willow Rd.
United States - Map
+1-650-5218000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company's Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Based on the Company's SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.

Officers and directors

Michael W. Hunkapiller Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Susan K. Barnes Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 61
Bio & Compensation  - Reuters
Kevin P. Corcoran Senior Vice President - Market Development
Age: 52
Bio & Compensation  - Reuters
Michael Phillips Senior Vice President - Research and Development
Age: 64
Bio & Compensation  - Reuters
William Ericson Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
David Botstein Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Brook H. Byers Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Randy Livingston Independent Director
Age: 61
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters